MicroRNA-193b Acts As a Tumor Suppressor in Colon Cancer Progression Via Targeting RAB22A

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2019 Apr 23

PMID 31007734

Citations 4

Authors

Zhiming Fang

Chengren Li

Shouchao Li

Affiliations

Soon will be listed here.

Abstract

To explore microRNA (miR)-193b expression and its potential role in colon cancer, reverse transcription-quantitative polymerase chain reaction was performed to detect the miR-193b expression levels in 62 colon cancer tissues and normal adjacent tissues. The miR-193b-overexpressed cell line SW620 was used to study the role of miR-193b in colon cancer. Subsequently, a Transwell assay and cell cycle assay were performed to observe the functional cell changes in the expression levels of miR-193b. Results indicated that miR-193b expression levels were significantly decreased in colon cancer tissues compared with adjacent normal tissue (P<0.001) and the expression of miR-193b was significantly correlated with TNM staging (P=0.03) and lymph node invasion (P=0.007). Furthermore, overexpression of miR-193b significantly decreased colon cancer cell cycle progression and its migration ability. In addition, the present findings suggested that the increased expression of miR-193b by RAB22A, inhibited downstream proteins involved in the Ras signaling pathway, including the Ras and extracellular signal-related kinase which may inhibit cancer proliferation and migration. In conclusion, the aim was to clarify the association of miR-193b expression with colon cancer, and to explore the mechanism of miR-193b in colon cancer proliferation and cell migration. The preliminary findings revealed that miR-193b may have an important role in the process in colon cancer cell cycle and migration by the RAB22A-Ras signaling pathway, thus providing a theoretical basis for miR-193b as a potential molecular target for colon cancer treatment.

Citing Articles

Insights into the complex interactions between Rab22a and extracellular vesicles in cancers.

Huang S, Bao Y, Kong L, Gao S, Hua C Inflamm Res. 2023; 73(1):99-110.

PMID: 38066108 DOI: 10.1007/s00011-023-01821-0.

The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer.

Lang C, Lloyd M, Alyacoubi S, Rahman S, Pickering O, Underwood T Cancers (Basel). 2022; 14(5).

PMID: 35267476 PMC: 8909542. DOI: 10.3390/cancers14051171.

Comprehensive Analysis of Expression, Clinicopathological Association and Potential Prognostic Significance of RABs in Pancreatic Cancer.

Anand S, Khan M, Khushman M, Dasgupta S, Singh S, Singh A Int J Mol Sci. 2020; 21(15).

PMID: 32759795 PMC: 7432855. DOI: 10.3390/ijms21155580.

MicroRNA-937 is overexpressed and predicts poor prognosis in patients with colon cancer.

Liu H, Ma L, Wang L, Yang Y Diagn Pathol. 2019; 14(1):136.

PMID: 31856857 PMC: 6923914. DOI: 10.1186/s13000-019-0920-3.

References

Opdam F, Kamps G, Croes H, van Bokhoven H, Ginsel L, Fransen J . Expression of Rab small GTPases in epithelial Caco-2 cells: Rab21 is an apically located GTP-binding protein in polarised intestinal epithelial cells. Eur J Cell Biol. 2000; 79(5):308-16. DOI: 10.1078/S0171-9335(04)70034-5. View

Mesa R, Salomon C, ROGGERO M, Stahl P, Mayorga L . Rab22a affects the morphology and function of the endocytic pathway. J Cell Sci. 2001; 114(Pt 22):4041-9. DOI: 10.1242/jcs.114.22.4041. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Kauppi M, Simonsen A, Bremnes B, Vieira A, Callaghan J, Stenmark H . The small GTPase Rab22 interacts with EEA1 and controls endosomal membrane trafficking. J Cell Sci. 2002; 115(Pt 5):899-911. DOI: 10.1242/jcs.115.5.899. View

Chiu V, Bivona T, Hach A, Sajous J, Silletti J, Wiener H . Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol. 2002; 4(5):343-50. DOI: 10.1038/ncb783. View

He H, Dai F, Yu L, She X, Zhao Y, Jiang J . Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr. 2002; 10(5-6):231-42. PMC: 5977521. DOI: 10.3727/000000002783992406. View

Chiu B, Ji B, Dai Q, Gridley G, McLaughlin J, Gao Y . Dietary factors and risk of colon cancer in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2003; 12(3):201-8. View

Hou L, Ji B, Blair A, Dai Q, Gao Y, Chow W . Commuting physical activity and risk of colon cancer in Shanghai, China. Am J Epidemiol. 2004; 160(9):860-7. DOI: 10.1093/aje/kwh301. View

Mesa R, Magadan J, Barbieri A, Lopez C, Stahl P, Mayorga L . Overexpression of Rab22a hampers the transport between endosomes and the Golgi apparatus. Exp Cell Res. 2005; 304(2):339-53. DOI: 10.1016/j.yexcr.2004.11.017. View

10.

Fengju S, Guanglin W, Kexin C . Incidence of colon cancer in Tianjin, China, 1981-2000. Asia Pac J Public Health. 2005; 17(1):22-5. DOI: 10.1177/101053950501700106. View

11.

Akao Y, Nakagawa Y, Naoe T . let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull. 2006; 29(5):903-6. DOI: 10.1248/bpb.29.903. View

12.

Roberts P, Der C . Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26(22):3291-310. DOI: 10.1038/sj.onc.1210422. View

13.

Tazawa H, Tsuchiya N, Izumiya M, Nakagama H . Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A. 2007; 104(39):15472-7. PMC: 2000550. DOI: 10.1073/pnas.0707351104. View

14.

Lassmann S, Kreutz C, Schoepflin A, Hopt U, Timmer J, Werner M . A novel approach for reliable microarray analysis of microdissected tumor cells from formalin-fixed and paraffin-embedded colorectal cancer resection specimens. J Mol Med (Berl). 2008; 87(2):211-24. DOI: 10.1007/s00109-008-0419-y. View

15.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

16.

Li X, Yan P, Shao Z . Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene. 2009; 28(44):3937-48. DOI: 10.1038/onc.2009.245. View

17.

Chen J, Feilotter H, Pare G, Zhang X, Pemberton J, Garady C . MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol. 2010; 176(5):2520-9. PMC: 2861116. DOI: 10.2353/ajpath.2010.091061. View

18.

Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J . MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer. 2010; 46(15):2828-36. DOI: 10.1016/j.ejca.2010.06.127. View

19.

Hu H, Krasinskas A, Willis J . Perspectives on current tumor-node-metastasis (TNM) staging of cancers of the colon and rectum. Semin Oncol. 2011; 38(4):500-10. DOI: 10.1053/j.seminoncol.2011.05.004. View

20.

Schneider B, Nagel S, Ehrentraut S, Kaufmann M, Meyer C, Geffers R . Neoplastic MiR-17~92 deregulation at a DNA fragility motif (SIDD). Genes Chromosomes Cancer. 2011; 51(3):219-28. DOI: 10.1002/gcc.20946. View